Hamza Saidi1, Luke R Smart2,3, Erasmus Kamugisha4, Emmanuela E Ambrose5, Deogratias Soka1, Robert N Peck2,3, Julie Makani1,6. 1. Muhimbili Wellcome Programme, Department of Haematology and Blood Transfusion, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania. 2. Department of Medicine, Weill Bugando School of Medicine, Catholic University of Health and Allied Sciences, Mwanza, Tanzania. 3. Department of Medicine, Weill Cornell Medical College, New York, NY, USA. 4. Department of Biochemistry, Weill Bugando School of Medicine, Catholic University of Health and Allied Sciences, Mwanza, Tanzania. 5. Department of Paediatrics, Weill Bugando School of Medicine, Catholic University of Health and Allied Sciences, Mwanza, Tanzania. 6. Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Abstract
OBJECTIVES: Tanzania has the third highest birth rate of sickle cell anaemia (SCA) in Africa, but few studies describe severity of complications or available treatments, especially in Northwest Tanzania around Lake Victoria where the sickle gene is most prevalent. This is a report of the spectrum of clinical disease and range of interventions available at Bugando Medical Centre (Bugando) in Northwest Tanzania in Africa. METHODS: A cross-sectional study was carried out in Bugando between 1 August 2012 and 30 September 2012. Children (<15 years old) with SCA attending Bugando were sequentially enrolled. A trained research assistant completed a Swahili questionnaire with the parent or guardian of each participant concerning demographic information, clinical features of disease, and treatments received. RESULTS: Among the 124 participants enrolled, the median age was 6 years (interquartile range [IQR] 4-8.5), and only 13 (10.5%) were < 3 years old. Almost all participants (97.6%) had a prior history of a vaso-occlusive episode, 83 (66.9%) had prior acute chest syndrome, and 21 (16.9%) had prior stroke. In the preceding 12 months, 120 (96.8%) had been hospitalized, and a vaso-occlusive episode was the most common reason for hospitalization (35.5%). Prescriptions for folic acid (92.7%) and malaria prophylaxis (84.7%) were common, but only one had received a pneumococcal vaccine, and none had received hydroxyurea or prophylactic penicillin. CONCLUSION: Children with SCA receiving care in Tanzania are diagnosed late, hospitalized frequently, and have severe complications. Opportunities exist to improve care through wider access to screening and diagnosis as well as better coordination of comprehensive care.
OBJECTIVES: Tanzania has the third highest birth rate of sickle cell anaemia (SCA) in Africa, but few studies describe severity of complications or available treatments, especially in Northwest Tanzania around Lake Victoria where the sickle gene is most prevalent. This is a report of the spectrum of clinical disease and range of interventions available at Bugando Medical Centre (Bugando) in Northwest Tanzania in Africa. METHODS: A cross-sectional study was carried out in Bugando between 1 August 2012 and 30 September 2012. Children (<15 years old) with SCA attending Bugando were sequentially enrolled. A trained research assistant completed a Swahili questionnaire with the parent or guardian of each participant concerning demographic information, clinical features of disease, and treatments received. RESULTS: Among the 124 participants enrolled, the median age was 6 years (interquartile range [IQR] 4-8.5), and only 13 (10.5%) were < 3 years old. Almost all participants (97.6%) had a prior history of a vaso-occlusive episode, 83 (66.9%) had prior acute chest syndrome, and 21 (16.9%) had prior stroke. In the preceding 12 months, 120 (96.8%) had been hospitalized, and a vaso-occlusive episode was the most common reason for hospitalization (35.5%). Prescriptions for folic acid (92.7%) and malaria prophylaxis (84.7%) were common, but only one had received a pneumococcal vaccine, and none had received hydroxyurea or prophylactic penicillin. CONCLUSION:Children with SCA receiving care in Tanzania are diagnosed late, hospitalized frequently, and have severe complications. Opportunities exist to improve care through wider access to screening and diagnosis as well as better coordination of comprehensive care.
Authors: P Pino; Z Taoufiq; M Brun; M Tefit; J F Franetich; L Ciceron; R Krishnamoorthy; D Mazier Journal: Parasite Immunol Date: 2006-12 Impact factor: 2.280
Authors: Natasha B Halasa; Sadhna M Shankar; Thomas R Talbot; Patrick G Arbogast; Ed F Mitchel; Winfred C Wang; William Schaffner; Allen S Craig; Marie R Griffin Journal: Clin Infect Dis Date: 2007-04-18 Impact factor: 9.079
Authors: Samir K Ballas; Susan Lieff; Lennette J Benjamin; Carlton D Dampier; Matthew M Heeney; Carolyn Hoppe; Cage S Johnson; Zora R Rogers; Kim Smith-Whitley; Winfred C Wang; Marilyn J Telen Journal: Am J Hematol Date: 2010-01 Impact factor: 10.047
Authors: Courtney D Thornburg; Beatrice A Files; Zhaoyu Luo; Scott T Miller; Ram Kalpatthi; Rathi Iyer; Phillip Seaman; Jeffrey Lebensburger; Ofelia Alvarez; Bruce Thompson; Russell E Ware; Winfred C Wang Journal: Blood Date: 2012-08-22 Impact factor: 22.113
Authors: F M Gill; L A Sleeper; S J Weiner; A K Brown; R Bellevue; R Grover; C H Pegelow; E Vichinsky Journal: Blood Date: 1995-07-15 Impact factor: 22.113
Authors: Thales Allyrio Araújo de Medeiros Fernandes; Tereza Maria Dantas de Medeiros; Jayra Juliana Paiva Alves; Christiane Medeiros Bezerra; José Veríssimo Fernandes; Édvis Santos Soares Serafim; Maria Zélia Fernandes; Maria de Fatima Sonati Journal: Rev Bras Hematol Hemoter Date: 2015-04-14
Authors: Emmanuela E Ambrose; Julie Makani; Neema Chami; Tulla Masoza; Rogatus Kabyemera; Robert N Peck; Erasmus Kamugisha; Alphaxard Manjurano; Neema Kayange; Luke R Smart Journal: Pediatr Blood Cancer Date: 2017-08-02 Impact factor: 3.167
Authors: Lianna J Marks; Deogratias Munube; Philip Kasirye; Ezekiel Mupere; Zhezhen Jin; Philip LaRussa; Richard Idro; Nancy S Green Journal: Glob Pediatr Health Date: 2018-05-14